All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Advances in PV Management Increase Hepcidin Levels and Improve Disease Burden

January 13th 2025

Naseema Gangat, MBBS, discusses the role of rusfertide for decreasing phlebotomy needs and the potential future for disease-modifying PV management.

BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies

January 12th 2025

Michael T. Tees, MD, MPH, describes how BTK degraders represent a promising class of agents, highlighting the agent AC676 that is currently under evaluation.

The OncFive: Top Oncology Articles for the Week of 1/5

January 11th 2025

Sunvozertinib gets priority review in EGFR-mutated NSCLC, iparomlimab/tuvonralimab combination elicits responses in cervical cancer, and more.

EMA Grants Orphan Medical Product Designation to Elraglusib in Advanced PDAC

January 11th 2025

An orphan medicinal product designation was granted to elraglusib by the EMA for patients with advanced pancreatic ductal adenocarcinoma.

Emiltatug Ledadotin Generates Positive Initial Data in Advanced/Metastatic Solid Tumors

January 10th 2025

Emiltatug ledadotin produced positive initial phase 1 data in breast, ovarian, and endometrial cancer, as well as adenoid cystic carcinoma type 1.

Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung

January 10th 2025

Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm

January 10th 2025

Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.

LSU Health Professor, Dr. Lucio Miele, Appointed as Director of LSU-LCMC Health Cancer Center

January 10th 2025

Lucio Miele, MD, PhD of LSU has been appointed as director of the LSU-LCMC Health Cancer Center.

ctDNA Testing Joins NCCN Guidelines for MRD Assessment in DLBCL

January 10th 2025

The NCCN Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment.

Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC

January 10th 2025

Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.

BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC

January 10th 2025

BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.

Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm

January 10th 2025

Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.

GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma

January 10th 2025

The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.

First-Line Belzutifan/Cabozantinib Delivers Responses and Manageable Toxicities in ccRCC

January 9th 2025

Frontline belzutifan plus cabozantinib elicited durable responses and was tolerable in patients with treatment-naive advanced ccRCC.

FDA Grants Orphan Drug Designation to Amezalpat for Advanced HCC

January 9th 2025

The FDA has granted orphan drug designation for the treatment of patients with hepatocellular carcinoma.

Mount Sinai’s Nina Bhardwaj Elected to National Academy of Medicine for Contributions to Cancer Immunotherapy

January 9th 2025

Nina Bhardwaj, MD, PhD, of Mount Sinai has been elected to the National Academy of Medicine for her pioneering work in cancer immunotherapy.

Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL

January 9th 2025

Supriya Gupta, MD, details pros/cons with different BTK inhibitors and promising combination therapies in CLL, as well as how liso-cel is affecting care.

ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR

January 9th 2025

The phase 3 ARES trial of MaaT013 in third-line GI-aGVHD met its primary end point of GI-ORR at day 28.

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma

January 9th 2025

Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.

Blinatumomab Becomes Standard Addition to Consolidation Chemo in B-ALL, Irrespective of MRD Status

January 9th 2025

Daniel DeAngelo, MD, PhD, discusses the expanded role of blinatumomab in B-cell precursor acute lymphoblastic leukemia management